- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06362668
EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU) (FASTR-EU)
April 8, 2024 updated by: Reprieve Cardiovascular, Inc
EU Sites: Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) (FASTR-EU)
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure (ADHF).
The main objective is to determine if the Reprieve DMS is non-inferior to state-of-the-art urine sodium guided aggressive diuretic titration in two European HF centers of excellence.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tony Fields
- Phone Number: 650-224-3884
- Email: tfields@reprievecardio.com
Study Locations
-
-
-
Groningen, Netherlands
- University Medical Center Groningen
-
Contact:
- Kevin Damman, MD
-
-
-
-
-
Wrocław, Poland
- Wroclaw Medical University
-
Contact:
- Jan Biegus, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Hospitalized with a diagnosis of heart failure as defined by the presence of at least 1 symptom AND 1 sign.
- ≥10 pounds (4.5 kg) above dry weight either by historical weights or as estimated by health care provider.
- Prior use of loop diuretics within 30 says prior to admission.
Exclusion Criteria:
- Inability to place Foley catheter or IV catheter.
- Hemodynamic instability.
- Dyspnea due primarily to non-cardiac causes.
- Acute infection with evidence of systemic involvement.
- Inability to follow instructions or comply with follow-up procedures.
- Other concomitant disease or condition that investigator deems unsuitable for the study, including drug or alcohol abuse or psychiatric, behavioral or cognitive disorders, sufficient to interfere with the patient's ability to understand and comply with the study instructions or follow-up procedures.
- Severe electrolyte abnormalities.
- Presence of active coronavirus disease 2019 (COVID-19) infection.
- Enrollment in another interventional trial during the index hospitalization.
- Inability of the patient to stand and obtain daily standing weights.
- Inability to return for follow-up study visits.
- Life expectancy less than 3 months.
- Women who are pregnant or intend to become pregnant.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Reprieve Decongestion Management System
Subjects randomized to Reprieve System will receive personalized and optimized diuretic and saline infusion using the study device during the course of the treatment.
|
The Reprieve Decongestion Management System, or Reprieve DMS, is a hospital bedside fluid management console designed to provide personalized and automated infusion of the IV diuretic furosemide and physiological saline in response to the patient's real-time urine output to safely and rapidly decongest patients suffering from Acute Decompensated Heart Failure.
|
Active Comparator: Optimal Diuretic Therapy
Sites will consider best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials [Diuretic Strategies in Patients with Acute Heart Failure Trail (DOSE), Acetazolamide in Decompensated Heart Failure with Volume Overload Trial (ADVOR), and Safety and Efficacy of the Combination of Loop with Thiazide-type Diuretics in Patients with Decompensated Heart Failure Trial (CLOROTIC)] for patients randomized to control arm of the trial.
|
Best practices of optimal diuretic dosing such as those demonstrated in recent randomized trials (DOSE, ADVOR, CLOROTIC).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total sodium loss (in mmol of sodium) per 24 hours
Time Frame: End of treatment, an average of 72 hours
|
Primary efficacy endpoint is total sodium loss in mmol of sodium at end of randomized therapy normalized to 24 hours (up to a maximum of 72 hours).
|
End of treatment, an average of 72 hours
|
Comparison of occurrence of composite endpoint comprised of clinically significant acute kidney injury, severe electrolyte abnormality, or symptomatic hypotension or hypertensive emergency.
Time Frame: Through study completion, an average of 90 days
|
Primary safety endpoint is positive if any of the following occurs in an individual participant:
|
Through study completion, an average of 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total net fluid volume loss (difference between urine output volume and fluid input volume) per 24 hours
Time Frame: End of treatment, an average of 72 hours
|
Difference between volume of urine output and fluid input during primary treatment normalized to 24 hours.
|
End of treatment, an average of 72 hours
|
Weight loss per 24 hours at end of randomized therapy
Time Frame: End of treatment, an average of 72 hours
|
Total time on loop diuretics during primary treatment
|
End of treatment, an average of 72 hours
|
Time on IV loop diuretic
Time Frame: End of treatment, an average of 72 hours
|
Total time on loop diuretics from initiation of randomized therapy to last dose of IV loop diuretic administered for ADHF
|
End of treatment, an average of 72 hours
|
Number of participants with ≥ 0.3 mg/dL increase in serum creatinine
Time Frame: End of treatment, an average of 72 hours
|
In hospital worsening renal function defined as ≥ 0.3 mg/dL increase in serum creatinine during randomized therapy.
|
End of treatment, an average of 72 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 9, 2024
Primary Completion (Estimated)
October 1, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
February 21, 2024
First Submitted That Met QC Criteria
April 8, 2024
First Posted (Actual)
April 12, 2024
Study Record Updates
Last Update Posted (Actual)
April 12, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Enzyme Inhibitors
- Carbonic Anhydrase Inhibitors
- Natriuretic Agents
- Membrane Transport Modulators
- Anticonvulsants
- Sodium Chloride Symporter Inhibitors
- Sodium Potassium Chloride Symporter Inhibitors
- Acetazolamide
- Hydrochlorothiazide
- Furosemide
- Diuretics
- Bumetanide
- Torsemide
Other Study ID Numbers
- RCV-0006-EU
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Decompensated Heart Failure
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Medical University of WarsawMedical University of Graz; Medical University of Vienna; Poznan University of... and other collaboratorsRecruitingAcute Decompensated Heart FailurePoland
-
Yooyoung Pharmaceutical Co., Ltd.RecruitingAcute Decompensated Heart FailureKorea, Republic of
-
Cardionomic Inc.Completed
-
Scripps HealthWithdrawnAcute Decompensated Heart FailureUnited States
-
Christian SchulzeBoehringer Ingelheim; Zentrum für Klinische Studien JenaCompletedAcute Decompensated Heart FailureGermany
-
Wake Forest University Health SciencesNational Institute on Aging (NIA)CompletedAcute Decompensated Heart FailureUnited States
-
Prof. Dr. Jörg LeuppiCompletedAcute Decompensated Heart FailureSwitzerland
-
Byung-Hee OhNational Institute of Health, KoreaCompletedAcute Decompensated Heart FailureKorea, Republic of
-
Trevena Inc.CompletedAcute Decompensated Heart FailureUnited States, Bulgaria, Poland, Russian Federation, Germany, Romania, Argentina, Canada, Czechia, Hungary, Israel, Slovakia
Clinical Trials on Reprieve Decongestion Management System
-
Reprieve Cardiovascular, IncRecruitingAcute Decompensated Heart FailureUnited States
-
Reprieve Cardiovascular, IncCompleted
-
BlueWind MedicalCompletedPeripheral NeuropathyBelgium, Poland
-
BlueWind MedicalCompleted
-
Radiant MedicalTerminatedAcute Myocardial InfarctionUnited States
-
Radiant MedicalTerminatedRenal Insufficiency | Renal Failure | Kidney FailureUnited States
-
CardioRenal Systems, Inc.Unknown
-
Reprieve Cardiovascular, IncRecruiting
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Krebsforschung Schweiz, Bern, Switzerland; Rising Tide FoundationRecruitingLymphedema, Breast CancerSpain, Switzerland, United States, Germany, Argentina, Austria, Belgium, Brazil, Canada, Greece, Italy, Netherlands, Romania, Sweden